- Home
- PAM vs CORT Comparison
PAM vs CORT Comparison
Compare PAM & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAM | CORT |
|---|---|---|
| Founded | 1945 | 1998 |
| Country | Argentina | United States |
| Employees | 1847 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.7B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | PAM | CORT |
|---|---|---|
| Price | $88.14 | $83.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $94.50 | ★ $96.50 |
| AVG Volume (30 Days) | 225.1K | ★ 952.2K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $204,770.38 | $26.08 |
| Revenue Next Year | $16.65 | $26.98 |
| P/E Ratio | $13.79 | ★ N/A |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $54.95 | $28.66 |
| 52 Week High | $94.50 | $91.00 |
Technical Indicators
Market Signals| Indicator | PAM | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 61.21 | 87.00 |
| Support Level | $78.87 | $68.20 |
| Resistance Level | $89.81 | $90.00 |
| Average True Range (ATR) | 3.32 | 3.21 |
| MACD | 0.45 | 0.96 |
| Stochastic Oscillator | 81.06 | 94.64 |
Price Performance
Historical ComparisonAbout PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.